Eiger Mountains

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
- HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline - Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating PALO ALTO, Calif. , April 1, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif., March 23, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA - Progeria NDA Submission Complete by End of March 2020 - Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif. , March 13, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Launch Preparation Underway for Lonafarnib in Progeria - Market Development Activities Advancing for HDV Program PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and
View HTML
Toggle Summary Eiger Updates on 2019 Progress and 2020 Milestones Expected
- Progeria Rolling NDA Planned for Completion in 1Q 2020 - HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 - Commercial Focus on Progeria Launch Preparation and HDV Market Building - Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif. , Jan.
View HTML